Patient must adhere to 8-hour fasting from solids and 4-hour fasting from clear liquids. Pre-operative assessment includes coagulation profile screening, cardiac clearance, and review of antiplatelet/anticoagulant medications which must be held according to institutional guidelines. Prophylactic intravenous antibiotics are administered prior to induction of anesthesia.
Admission to the surgical ward is mandatory. Monitor for signs of delayed perforation or bleeding (post-ESD hemorrhage). Initiate liquid diet within 24 hours, progressing to a soft diet over 3-5 days. Proton pump inhibitors are prescribed for 8 weeks to facilitate healing. Discharge occurs once the patient tolerates oral intake and displays no signs of systemic inflammatory response.
Comprehensive Guide: Gastric Endoscopic Submucosal Dissection (ESD)
Endoscopic Submucosal Dissection (ESD) represents a paradigm shift in the management of early-stage gastric neoplasms. As a minimally invasive, organ-sparing technique, ESD allows for the en bloc resection of lesions that were historically relegated to surgical gastrectomy. By providing superior histopathological assessment compared to piecemeal resection techniques like Endoscopic Mucosal Resection (EMR), ESD has become the gold standard for curative endoscopic therapy in the upper gastrointestinal tract.
1. Introduction & Clinical Overview
Gastric ESD is an advanced endoscopic procedure designed to remove superficial gastric tumors—specifically those confined to the mucosa or superficial submucosa—with high precision. Unlike traditional surgery, which involves partial or total resection of the stomach, ESD preserves the organ, significantly enhancing the patient’s quality of life (QoL) and reducing long-term morbidity associated with post-gastrectomy syndrome.
The Paradigm Shift
The transition from surgery to ESD is predicated on the "low risk of lymph node metastasis" (LNM) in early gastric cancer (EGC). When lesions are within specific depth and size criteria, the oncological outcomes of ESD are non-inferior to surgery, while the procedural risk profile remains significantly lower.
2. Technical Specifications and Mechanisms
The procedure relies on specialized electrosurgical knives and high-definition imaging systems to create a plane of dissection within the submucosal layer.
The Procedural Workflow
- Marking: Using a needle-knife or coagulation forceps, the clinician marks the periphery of the lesion, typically 5–10 mm outside the visual margins.
- Submucosal Injection: A solution (typically saline, glycerol, or hyaluronic acid mixed with epinephrine and indigo carmine) is injected into the submucosa to lift the lesion away from the muscularis propria. This "cushion" is critical for preventing thermal injury to the deeper layers.
- Circumferential Incision: Using an ESD-specific knife (e.g., Dual Knife, IT-Knife, or FlushKnife), the mucosa surrounding the lesion is incised.
- Submucosal Dissection: The submucosal fibers are meticulously dissected to separate the lesion from the underlying muscularis propria until the entire specimen is liberated.
Essential Equipment
| Equipment Category | Examples |
|---|---|
| Endoscopes | Dual-channel or high-definition gastroscope |
| Electrosurgical Units | VIO 300D (ERBE) with specific Endo-Cut settings |
| ESD Knives | Dual Knife, IT-Knife 2, FlushKnife, SB Knife |
| Injection Agents | Sodium Hyaluronate (e.g., MucoUp), Glycerol, Saline |
| Hemostatic Tools | Coagrasper, Hemoclips, Endoloops |
3. Clinical Indications and Usage
The decision to perform ESD is governed by strict adherence to the Japanese Gastric Cancer Association (JGCA) guidelines.
Absolute Indications (Curative Criteria)
- Differentiated-type intramucosal carcinoma without ulceration, regardless of lesion size.
- Differentiated-type intramucosal carcinoma with ulceration, ≤ 3 cm.
- Undifferentiated-type intramucosal carcinoma without ulceration, ≤ 2 cm.
Expanded Indications
- Differentiated-type carcinoma with invasion into the superficial submucosa (SM1 < 500 µm), ≤ 3 cm.
- Differentiated-type intramucosal carcinoma with ulceration, > 3 cm.
Contraindications
- Lesions with deep submucosal invasion (SM2 or greater).
- Presence of lymph node or distant metastasis.
- Uncontrolled coagulopathy or bleeding disorders.
- Severe cardiopulmonary instability that precludes prolonged sedation.
4. Patient Pre-Operative Preparation
Success in ESD is heavily dependent on meticulous preparation to mitigate risks of bleeding and perforation.
- Anticoagulation Management: Patients on antiplatelet or anticoagulant therapy must follow standardized bridging protocols. Aspirin may often be continued, but P2Y12 inhibitors (e.g., clopidogrel) generally require cessation 5–7 days prior.
- Imaging: Pre-operative EUS (Endoscopic Ultrasound) is often employed to assess the depth of invasion and detect potential lymph node involvement.
- Anesthesia: ESD is typically performed under deep sedation or general anesthesia with endotracheal intubation to ensure patient immobilization and airway protection during the prolonged procedure.
5. Post-Operative Recovery and Protocol
The recovery phase focuses on the prevention of delayed bleeding and the monitoring for delayed perforation.
Immediate Post-Op Care
- Observation: The patient is monitored in a recovery unit for 2–4 hours.
- Diet: Patients are usually kept NPO (nothing by mouth) for the remainder of the day. A liquid diet is typically initiated 24 hours post-procedure, progressing to a low-fiber diet over the next 3–5 days.
- Pharmacotherapy: Proton Pump Inhibitors (PPIs) are administered intravenously or orally for 4–8 weeks to facilitate ulcer healing and reduce the risk of delayed bleeding.
Monitoring for Complications
- Delayed Bleeding: Usually occurs within 72 hours to 1 week post-procedure. Symptoms include hematemesis or melena.
- Delayed Perforation: Rare, but can present with signs of peritonitis, fever, or severe abdominal pain.
6. Risks, Side Effects, and Complications
While ESD is minimally invasive, it carries inherent risks requiring expert intervention.
- Perforation: Occurs in 1–5% of cases. Most are managed endoscopically with clips or OTSC (Over-The-Scope Clips).
- Delayed Bleeding: The most common complication (3–7%). Managed via repeat endoscopy and hemostatic measures.
- Stricture Formation: Primarily a concern when the lesion involves >75% of the gastric circumference (e.g., near the cardia or pylorus).
- Aspiration Pneumonia: A risk associated with prolonged sedation and the supine position.
7. Alternative Treatments
- Surgical Gastrectomy (Laparoscopic or Open): The standard for lesions that fail to meet curative ESD criteria or for those showing signs of deep invasion.
- Endoscopic Mucosal Resection (EMR): Suitable for small, superficial lesions (<10 mm) where en bloc resection is easily achieved. EMR is generally contraindicated for larger lesions due to high recurrence rates.
- Radiofrequency Ablation (RFA): Rarely used for gastric cancer; generally reserved for Barrett’s esophagus or palliative scenarios.
8. Frequently Asked Questions (FAQ)
1. Is ESD as effective as surgery for gastric cancer?
For lesions meeting the curative criteria, ESD provides oncological outcomes equivalent to surgery with significantly lower morbidity.
2. How long does the procedure take?
Depending on the size, location, and fibrosis of the lesion, the procedure typically lasts between 60 and 180 minutes.
3. Will I need to stay in the hospital?
Most centers require a 2–3 day hospital stay to monitor for delayed post-operative bleeding.
4. What is the success rate of ESD?
The en bloc resection rate for experienced endoscopists is generally >95%.
5. Does the cancer come back after ESD?
If the lesion is resected with negative horizontal and vertical margins (R0 resection), the recurrence rate is extremely low (<1%).
6. Can I eat normally after the procedure?
You will start on a clear liquid diet and gradually transition to a soft, low-fiber diet over the course of one week.
7. What if the pathology report shows the margins are not clear?
If the resection is incomplete (R1), a follow-up discussion with a multidisciplinary team is necessary to decide between repeat ESD or surgical resection.
8. Is anesthesia required?
Yes, due to the length and precision required, deep sedation or general anesthesia is standard practice to ensure the stomach remains stable.
9. What are the common symptoms after the procedure?
Mild abdominal discomfort or bloating is common. Severe pain, fever, or vomiting should be reported to the medical team immediately.
10. How often do I need follow-up endoscopies?
Standard surveillance usually involves an endoscopy at 6 months and 12 months, followed by annual check-ups for at least 3–5 years.
9. Conclusion
Gastric ESD is a sophisticated, highly effective intervention that balances oncological rigor with patient-centered outcomes. Through the application of advanced endoscopic technology and adherence to strictly defined clinical indications, clinicians can provide curative treatment for early gastric cancers while preserving the stomach's structural and functional integrity. As endoscopic technology continues to evolve, the boundaries of ESD will likely expand further, solidifying its role as a cornerstone of modern gastroenterology.
Disclaimer: This guide is intended for educational purposes for healthcare professionals and patients. It does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified physician with any questions regarding a medical condition or procedure.